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Initial development of a patient-reported instrument assessing harm, 
efficacy, and misuse of long-term opioid therapy
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Abstract—Guidelines on long-term opioid therapy recom-
mend frequent reassessment of harm, efficacy, and misuse of 
these potentially harmful and sometimes ineffective medica-
tions. In primary care, there is a need for a brief, patient-
reported instrument. This report details the initial steps in the 
development of such an instrument. An interdisciplinary team 
of clinician-scientists performed four discrete steps in this 
study: (1) conceptualization of the purpose and function of the 
instrument, (2) assembly of an item pool, (3) expert rating on 
which items were most important to include in the instrument, 
and (4) modification of expert-selected items based on a read-
ing level check and cognitive interviews with patients. A 
diverse panel of 47 subject matter experts was presented with 
69 items to rate on a 1–9 scale in terms of importance for inclu-
sion in the instrument. The panel highly rated 37 items: 
8 related to harm, 4 related to efficacy, and 25 related to mis-
use. These 37 items were then tested for patient comprehension 
and modified as needed. Next steps in development will 
include further item reduction, testing against a gold standard, 
and assessment of the instrument’s effect on clinical outcomes.
Key words: chronic pain, efficacy, harm, instrument develop-
ment, misuse, opioid analgesics, opioid therapy, pain manage-
ment, patient reported, therapeutic monitoring.
INTRODUCTION
Patients and providers face complex challenges 
when managing long-term opioid analgesic therapy for 
chronic pain. Only a minority of patients may experience 
benefits from long-term opioid therapy [1–2], and this 
likelihood must be balanced against potential undesired 
outcomes, including safety issues ranging from mild toxici-
ties to overdose and death [3] and misuse of these potent 
medications. To help patients and providers optimize out-
comes and mitigate risks, experts advise a strategy of fre-
quent reassessment of harm, efficacy, and misuse in
patients on opioids to inform treatment decisions [4–5]. 
Assessment of harm, efficacy, and misuse of ongoing opi-
oid therapy can be achieved through patient report, e.g., 
querying patients about side effects and therapeutic 
effects, and other methods, such as performing urine drug 
testing to assess for use of unprescribed substances [6] or 
querying a prescription monitoring database for evidence 
of multiple prescribers [7]. While the latter strategies are 
generally recommended and may be useful in the catego-
ries of harm and misuse, systematic assessment of patient-
reported symptoms, emphasizing those that matter to
Abbreviations: IMMPACT = Initiative on Methods, Measure-
ment and Pain Assessment in Clinical Trials; PRIOR = Patient-
Reported Indications for Opioid Reassessment; VA = Department 
of Veterans Affairs; VHA = Veterans Health Administration.
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patients, has been recognized as a critical and often over-
looked piece of high-quality medication management in 
general [8–9] and of ongoing opioid therapy in particular 
[4,10].
Experts have identified the phenomenon of clinical 
inertia—not making a change in therapy that may be 
indicated—as one of the factors driving the ongoing 
unprecedented rates of opioid prescribing [11–12]. Fur-
thermore, there are emerging qualitative data from 
patients and providers about a troubling disconnect: the 
patient continues the therapy because the prescriber con-
tinues writing the prescriptions (not because the medica-
tion is effective) and the prescriber continues to write the 
prescriptions because of the untested assumption that the 
patient is satisfied with the treatment [13–14]. These 
findings drive our hypothesis that a brief instrument, pro-
tocolized into routine follow-up, may promote a more 
active surveillance approach and combat clinical inertia.
However, to date, there is no widely accepted, vali-
dated, patient-reported instrument available to monitor 
the harm, efficacy, and misuse of opioid therapy pre-
scribed for patients with chronic pain. A recent system-
atic review identified nine published instruments that 
assessed at least one of these categories, none of which 
had been tested in clinical practice [15]. This shortcom-
ing contributed to the conclusion that none of these 
instruments were comprehensive and feasible to imple-
ment in clinical practice. In light of this identified gap, 
our long-term goal is to develop such an instrument. The 
purpose of the present study was to describe the methods 
used to develop the preliminary version of an instrument 
designed to measure patient-reported harm, efficacy, and 
misuse of opioid therapy that will ultimately undergo fur-
ther testing.
METHODS
Overview of Study Design
We performed four discrete steps in this study: (1) con-
ceptualization of the purpose and function of the instru-
ment, (2) assembly of an item pool, (3) expert rating of 
items from the pool most important to include in the pre-
liminary version, and (4) modification of expert-selected 
items based on a reading level check and cognitive inter-
views with patients. Each component of the study was 
approved by the Department of Veterans Affairs (VA) Con-
necticut Healthcare System Human Subjects Subcommittee 
and the Yale University School of Medicine’s Institutional 
Review Board.
Purpose and Function of Instrument
We convened a core research team, composed of clini-
cian researchers with diverse training and experience in pri-
mary care/internal medicine, rheumatology, psychology, 
pain medicine, addiction medicine, nursing, psychometrics, 
and clinical epidemiology, to discuss the identified gap in 
opioid monitoring and establish the purpose and function of 
a new instrument. Consensus emerged that the instrument 
should be (1) developed for use in primary care, where most 
long-term opioid therapy is prescribed; (2) patient-reported 
and patient self-administered in order to improve efficiency 
and eliminate barriers to completion; (3) designed to be sen-
sitive to incipient or developing harms and low or absent 
benefit; (4) complementary to existing measures of pain and 
opioid misuse; and (5) designed such that one or more posi-
tive responses to items on the instrument would prompt a 
more detailed clinical assessment of each positive response. 
As such, there would be no scaling or scoring of the instru-
ment. We plan to name the final instrument the Patient-
Reported Indications for Opioid Reassessment (PRIOR).
Assembly of Item Pool
We first performed a systematic review to identify 
instruments containing patient self-reported items related 
to safety, efficacy, and misuse of opioid therapy [15] and 
sorted items from these instruments (n = 9) by category 
(safety, efficacy, misuse, or other). The core research 
team reached consensus on whether this pool lacked any 
important items by comparing the list of efficacy-related 
items to the Initiative on Methods, Measurement and 
Pain Assessment in Clinical Trials (IMMPACT) recom-
mended domains for assessing analgesic efficacy in clini-
cal trials [16] and comparing the list of harm-related 
items with a literature search of opioid-related harms. 
Beyond these two sources, a suitable item was identified 
from the broader medical literature for any specific con-
tent area identified as missing.
Eliminating Items
First, we removed items that did not directly pertain 
to harm, efficacy, or misuse of current opioid therapy. 
Next, we identified items with identical or near-identical 
syntax and removed those items judged to have less clear 
syntax. We then removed items that were not written in 
patient-reported format if the item’s content was covered 
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by a similar, patient-reported item. Since interpreting the 
clinical significance of single time point numeric ratings 
can be challenging [17], we removed items relying on 
numeric scales in the response if similar items not requir-
ing use of a numeric rating scale were available. Finally, 
in recognition that three of the instruments identified in 
the systematic review were designed for clinical research 
on opioid-induced constipation (the Bowel Function 
Index, the Patient Assessment of Constipation Symp-
toms, and the Bowel Function Diary) and contained a 
level of detail on constipation unnecessary for primary 
care-based screening, we chose three items that ade-
quately covered the concept of opioid-induced constipa-
tion rather than including all the constipation-related 
items.
Item Modification and Standardization
If a single item contained more than one content area, 
we revised it to create multiple items covering each one. 
For items not written in patient-reported format and if the 
content was not otherwise covered in one of the remaining 
items, we modified them into patient-reported format 
based on examples from the broader medical literature. To 
promote ease of evaluation by the expert panel and, ulti-
mately, use of the instrument in clinical practice, we stan-
dardized the items in three ways. First, we edited each 
item to include a common stem, “In the last 30 days . . .” 
to fit the planned use of the instrument multiple times per 
year. With our goal of developing an instrument sensitive 
to harm-related problems, asking a patient to evaluate a 
symptom and additionally whether that symptom was 
related to or caused by opioids seemed unnecessarily 
complex and a potential source of low sensitivity. There-
fore, when possible, we removed attribution of symptoms 
to opioids from items when such attribution was asked of 
the patient. If attribution was the crux of the question 
(e.g., “Have you been bothered by side effects of opioid 
pain medications?,” we did not modify the item. Last, we 
transformed each item into a question with a yes/no 
response, whereby the “yes” response would denote an 
issue of clinical significance requiring more detailed 
assessment.
Subject Matter Expert Item Rating
A priori, we defined a subject matter expert as some-
one who (1) believes that, at least in some instances, opi-
oids can be safely and effectively used for the treatment 
of chronic noncancer pain; (2) prescribes and manages 
opioids for chronic noncancer pain; and (3) has an estab-
lished clinical or research interest in chronic pain man-
agement. We used two sources to identify potential 
subject matter experts: (1) the Veterans Health Adminis-
tration (VHA) pain points of contact list, consisting of 
pain-interested clinicians responsible for dissemination 
and implementation of VHA pain-related policies at each 
VHA facility nationally (n = 108), and (2) the VHA pain 
research working group listserv, whose membership con-
sists of VHA pain-relevant investigators (n = 30).
As is increasingly common, our expert item-rating 
process used an Internet-based survey platform (Qual-
trics; Provo, Utah). We sent an email message to potential 
participants in which we provided a description of the 
project, noted the voluntary nature of participation, and 
embedded a link to the Web-based survey. In the survey, 
there were two screening questions regarding opioid ther-
apy for chronic noncancer pain and a short demographics 
section. After describing the purpose of the instrument, 
we presented the participants with 69 items, sorted by cat-
egory (harm, efficacy, or misuse), and asked them to rate 
each item on a 1–9 scale with respect to its importance for 
inclusion in the instrument (1 = not important, 9 = very 
important), based on the stated purpose of the instrument. 
Participants were asked to write in any items not listed 
that they believed should be included. Adapted from a 
published methodology [18], we identified the highly 
rated items using prespecified criteria: median response 
value of 8 or 9 with agreement, defined as 70 percent of 
values of 7, 8, or 9. We stipulated a priori that at least two 
items from each category would need to be present in the 
preliminary version of the instrument, even if they did not 
meet the definition of highly rated. We planned for the 
option of a second round of rating if there were new items 
suggested by subject matter experts or the absence of 
agreement on highly rated items.
Reading Level Check and Cognitive Interviews with 
Patients
An important step in the development of a patient-
reported instrument, especially one that will be self-
administered, is verifying that patients understand what 
the items mean [19]. To improve the comprehensibility of 
the items, we undertook two additional steps with the 
highly rated items: assessing the reading level of the 
items and performing cognitive interviews with patients 
on opioids. The reading level of each item was assessed 
using the Fog Index [20], which uses a scoring system of 
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reading level based on the numbers of words per sentence 
and the number of polysyllabic words per paragraph. 
Next, we performed cognitive interviews with patients in 
which, in 1:1 sessions, each patient was asked to read 
each item out loud and interpret, in his or her own words, 
what each item was asking. This “think aloud” procedure 
has been used in developing other patient-reported instru-
ments [21]. Modifications were made for any item for 
which there was recurrent confusion.  We conducted 
interviews until the most recent version was accurately 
interpreted by 10 consecutive participants.
RESULTS
Assembly of Item Pool
The Figure displays how the 129 items identified in 
the systematic review were reduced to the 69 items pre-
sented to the expert panel. Based on comparison to the 
domains recommended by IMMPACT, no items identified 
in the systematic review covered the specific efficacy-
related content areas “functional interference” and “emo-
tional interference.” Therefore, we added one item each 
from the National Institutes of Health’s Patient-Reported 
Outcomes Information System item bank related to these 
specific content areas [22]. Our literature review of opioid-
related harms revealed two adverse outcomes—falls [23] 
and motor vehicle accidents [24]—not accounted for in the 
item pool; thus, we added an item about each [25–26].
Eliminating Items
The largest group of eliminated items were not written 
in patient-reported format but contained content covered 
elsewhere (n = 24). As mentioned previously, for parsi-
mony while at the same time attempting to cover this com-
mon side effect, we retained three items related to 
constipation: “Have you been bothered by constipation?,” 
“Have you been bothered by hard stools?,” and “Have you 
been bothered by straining or squeezing to try to pass 
bowel movements?,” and removed the rest (n = 20). The 
next largest group of eliminated items (n = 14) was judged 
as not directly pertaining to harm, efficacy, and misuse of 
current opioid therapy. Several of these items were histori-
cal in nature, e.g., “Have you ever had a drug or alcohol 
addiction problem?,” and thus not practical for recurring 
use. Others sought to measure characteristics not directly 
related to the patient’s own experience of harm, efficacy, 
or misuse, for example, “Do any of your family members 
disagree with your use of pain medications?” We elimi-
nated 13 items with identical or nearly identical syntax to 
another item that was retained. For example, we consid-
ered “Is anyone in your family or among your friends con-
cerned that you might be addicted to pain medications?” 
and “Family or friends have thought that I may be depen-
dent on or addicted to opiate pain medications” nearly 
identical and eliminated the latter due to ambiguity of the 
term “dependent on.” Four items relying on numeric 
scales, e.g., “What percentage of your pain has been 
relieved during the past week?,” were eliminated.
Item Modification and Standardization
We divided items containing more than one component 
into single component items: for example, “I have felt 
depressed, down, or anxious” became “I have felt 
depressed,” “I have felt down,” and “I have felt anxious.” 
We replaced non–patient-reported items not covered else-
where with patient-reported versions. For example, the item 
“Ask patient about vomiting” was replaced by, “Have you 
been bothered by vomiting?,” gleaned from a patient-
reported instrument for gastric dysmotility [27]. Finally, to 
create binary items where a positive response was clinically 
meaningful, we inserted “bothered by” to reduce the possi-
bility that the patient would endorse the item based on a 
clinically trivial level of symptoms, for example, “In the 
past 30 days, have you been bothered by constipation?” 
replaced, “In the past 30 days, have you been constipated?”
Subject Matter Expert Item Rating
The response rate to the survey for potential subject 
matter experts was 54 percent (75/138). Of the 75 
respondents, 29 did not meet subject matter expert crite-
ria (2 did not believe that opioids could be safely and 
effectively used in the treatment of chronic noncancer 
pain and 27 did not prescribe and manage opioid therapy 
for chronic noncancer pain). Of the 47 subject matter 
experts, 23 were women (49%), half were in the 46 to 
55 yr age group, and each of VHA’s 21 geographically 
contiguous catchment areas was represented. The largest 
group of subject matter experts was trained in general 
internal medicine/family medicine/primary care (n = 19), 
followed by pain/anesthesiology (n = 15), with addiction 
medicine, neurology, nursing, physiatry/physical medi-
cine and rehabilitation, psychiatry, and rheumatology 
also represented. The expert panel highly rated 37 of the 
69 items based on the criteria described; see Appendix 1
(available online only) for complete results of the item 
Figure.
Item pool development. IMMPACT = Initiative on Methods, Measurement and Pain Assessment in Clinical Trials.
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rating process. Of the 37 highly rated items, 8 were 
related to harm, 4 were related to efficacy, and 25 were 
related to misuse. The median response value of each 
included harm-related item was 8, except “Have you felt 
sleepy or less alert when driving or operating machin-
ery?,” which had a median response value of 9. Since 
there was consensus on highly rated items and there were 
no new patient-reported items suggested by the expert 
panel, a second round of rating was not necessary.
In anticipation of further testing of the PRIOR in 
future studies, we consulted with the lead authors of the 
original instruments for permission to use their items. All 
but two authors granted permission, which affected two 
of the 37 items. For both items, we selected the next 
highest-rated item that was similar in content.
Reading Level Check and Cognitive Interviews
The reading level check did not lead to any item 
modifications because we had already shortened long 
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items in a previous step by breaking down multicompo-
nent single items into multiple single-component items. 
Additionally, there was a low density of polysyllabic 
words. There was, however, heterogeneity among the 
items in how opioids were referred to and also whether 
the term “physician” or “doctor” was used. Based on the 
cognitive interviewing process, we identified “opioid 
pain medication” and “doctor” as the universally under-
stood versions of these terms. Additionally, in the cogni-
tive interviewing process, we learned that several patients 
thought the word “sedated” meant “knocked out” or 
“unconscious”; therefore, we changed this term to
“overly drowsy” in keeping with other studies of cen-
trally acting, sedating medications [28]. Following our a 
priori established protocol, the cognitive interviewing 
process was complete when 10 consecutive subjects
interpreted all the items in the same way without confu-
sion, which occurred after 16 interviews. The preliminary 
version of the PRIOR is contained in Appendix 2 (avail-
able online only).
DISCUSSION
Through a multistep process, we developed a prelim-
inary version of the PRIOR, a patient-reported instrument 
for identifying opioid harm, low efficacy, and misuse 
among patients on long-term opioids. The PRIOR is 
designed to fill a gap based on systematic review of the 
literature; accordingly, we aimed for it to be comprehen-
sive, covering harm, efficacy, and misuse; to be patient-
reported and patient self-administered in order to 
improve efficiency and eliminate barriers to completion, 
especially in primary care; and to yield clinically action-
able information. Consistent with our goal of comprehen-
siveness, the subject matter expert panel in the present 
study highly rated at least four items from each of the 
harm, efficacy, and misuse categories. This spread of 
items across categories, while to some degree enforced 
by design, reflects the expert panel’s interest in not just 
assessing traditionally provider-centered concerns (i.e., 
misuse), but also patient-centered ones (e.g., harm and 
efficacy). Feasibility is yet to be established. However, at 
37 items, especially the 25 items related to misuse, this 
preliminary instrument is too long and will require fur-
ther item reduction to be used in busy primary care prac-
tices. While several design decisions should promote the 
clinical utility of the PRIOR, this will ultimately be 
determined by field testing of a briefer version in subse-
quent studies.
The strengths of this work include, first, the rigorous 
approach to understanding the current needs in opioid 
monitoring through systematic review and also gathering 
input from a diverse research team with broad expertise. 
Second, the process for item selection brought together a 
large, diverse group of subject matter experts who effi-
ciently arrived at consensus. Finally, the standardization 
of items and use of cognitive interviewing to ensure 
patient comprehension were critical steps often lacking in 
other instrument development processes.
A number of decisions in the design of the prelimi-
nary PRIOR deserve further discussion. The first is our 
decision to disaggregate previously validated multi-item 
instruments into their component items for voting by the 
expert panel. We considered this consistent with our 
overall conceptualization of the final PRIOR as a check-
list of symptoms and behaviors in which each item would 
have its own inherent meaning and, if positive, would 
indicate the need for further clinical assessment. Addi-
tionally, the use of items from previously validated 
instruments afforded the advantage that each item had 
already been tested to some degree for patient compre-
hension or other validity. The next decision was to 
include only VHA clinicians in the expert panel. In rec-
ognition of the fact that VHA routinely uses other related 
instruments in clinical settings (e.g., the pain numerical 
rating scale, Patient Health Questionnaire-2 for depres-
sion), we are designing the PRIOR for use in VHA and 
thus wanted input from experts who work in the VHA 
system. Finally, we included nurse practitioners and phy-
sician assistants in the expert panel since these clinicians 
function as primary care providers in the VHA system 
and thus can contribute the same breadth of experience 
and expertise to this process.
The current study has limitations. First, while disag-
gregating other instruments may ultimately contribute to 
a brief, feasible instrument, it is possible that accuracy 
may be compromised if certain symptoms or behaviors 
are better assessed with intact groups of items. We con-
sider this an acceptable trade-off of maximizing feasibil-
ity and sensitivity but sacrificing some specificity, which 
can be gained by the ensuing patient-provider discussion. 
Second, patient self-report of misuse may be inaccurate, 
especially when doing so may threaten future prescrip-
tions [29], and yet over half of the preliminary PRIOR is 
misuse-related. We expect that in future development 
133
BECKER et al. Development of PRIOR
steps, the number of misuse-related items will be reduced 
markedly; it may ultimately be determined that only one 
or two misuse-related items are worthwhile for use in a 
patient-reported instrument and that the bulk of the rele-
vant data would come from non–patient-reported assess-
ments such as urine drug tests, pill counts, and querying a 
prescription monitoring database.
CONCLUSIONS
As mentioned previously, next steps in this work 
include item reduction and field testing. To achieve that 
aim along with examining the psychometric properties of 
the instrument, we plan additional data collection and 
instrument analysis using Rasch methodology [30]. 
Patients taking opioids will self-administer the prelimi-
nary PRIOR as part of usual clinical care. Rasch analysis 
uses these data to create a hierarchy of the items on a uni-
dimensional spectrum of difficulty, allowing elimination 
of misfitting and overcorrelated items and providing evi-
dence for reliability and validity. Through this process, 
patient input will be incorporated since items that are 
never or very rarely endorsed will be dropped. The goal 
is to develop a briefer instrument with minimal respon-
dent burden, which we will then compare against a stan-
dardized in-depth clinical assessment, including corollary 
non–patient-reported measures (e.g., urine drug testing 
and querying a prescription monitoring database), and 
finally test in clinical practice for its effect on harm, effi-
cacy, and misuse-related outcomes. Our hypothesis is 
that the PRIOR will add significant value to the current 
standardized measures of pain intensity (e.g., the pain 
numerical rating scale) and opioid harm, but this hypoth-
esis should be tested before broad dissemination. This 
preliminary version of the PRIOR provides a strong 
foundation for these future efforts.
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